1933 Industries Inc (TGIFF) Fair Value & Analysis
Healthcare · US · Market cap $2.8M
1933 Industries Inc
TGIFF · US
Fair value as of: Aug 13, 2026
From 10 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from $0.0051 to $0.0059 (+16.8%) since Jul 31, 2026. Share price +30.8% over the past month.
Below-average quality, and screening another 13% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0059). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0027 – $0.0900 · the $0.0068 price screens above the $0.0059 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
1933 Industries Inc (TGIFF) currently trades at $0.0068, while our model-based Fair Value estimate is $0.0059, implying the stock looks roughly 13.2% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, 1933 Industries Inc generated revenue of $17.0M at a net margin of 2.8%. Revenue declined 10.6% year over year. Net debt stands at $2.9M. Fundamentals as of Aug 13, 2026
The share trades about 60% below its 52-week high and 119% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -13%, TGIFF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: DCF Models ($0.0400) versus Multiples ($0.0200). Highest evidence: Growth DCF (80).
Notify me when TGIFF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
1933 Industries Inc., together with its subsidiaries, engages in the cultivation, extraction, and production of cannabis products in the United States. It operates through AMA and Infused MFG segments.
Full company description
1933 Industries Inc., together with its subsidiaries, engages in the cultivation, extraction, and production of cannabis products in the United States. It operates through AMA and Infused MFG segments. The company offers craft-style cannabis, branded flower, infused pre-rolls, full spectrum oils, distillates, and blends of terpenes; vaporizer products and boutique concentrate, such as shatter, crumble, batter, sugar wax, diamonds, and cured and live resins under the AMA and Level X brands. It also provides cannabidiol, and cannabinol infused products. The company sells its products through licensed dispensaries, as well as direct to consumers via e-commerce at cannahemp.com. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. is headquartered in Vancouver, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
1933 Industries Inc reported revenue of $17.4M in FY2025 versus $12.0M in FY2021, a compound +9.9%/yr. Reported net income was −$217K in FY2025.
TGIFF screens 13% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare 1933 Industries Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 1933 Industries Inc (TGIFF) overvalued or undervalued?
What is the fair value of TGIFF?
What is the quality score of TGIFF?
What is the revenue of 1933 Industries Inc (TGIFF)?
What is the net profit margin of TGIFF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track 1933 Industries Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.